المؤلفون: Makrakis, Dimitrios, Talukder, Rafee, Diamantopoulos, Leonidas N, Carril-Ajuria, Lucia, Castellano, Daniel, De Kouchkovsky, Ivan, Koshkin, Vadim S, Park, Joseph J, Alva, Ajjai, Bilen, Mehmet A, Stewart, Tyler F, McKay, Rana R, Santos, Victor S, Agarwal, Neeraj, Jain, Jayanshu, Zakharia, Yousef, Morales-Barrera, Rafael, Devitt, Michael E, Grant, Michael, Lythgoe, Mark P, Pinato, David J, Nelson, Ariel, Hoimes, Christopher J, Shreck, Evan, Gartrell, Benjamin A, Sankin, Alex, Tripathi, Abhishek, Zakopoulou, Roubini, Bamias, Aristotelis, Murgic, Jure, Fröbe, Ana, Rodriguez-Vida, Alejo, Drakaki, Alexandra, Liu, Sandy, Kumar, Vivek, Di Lorenzo, Giuseppe, Joshi, Monika, Isaacsson-Velho, Pedro, Buznego, Lucia Alonso, Duran, Ignacio, Moses, Marcus, Barata, Pedro, Sonpavde, Guru, Yu, Evan Y, Wright, Jonathan L, Grivas, Petros, Khaki, Ali Raza

المصدر: BJU International, vol 130, iss 5

مصطلحات موضوعية: Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Good Health and Well Being, Humans, Immune Checkpoint Inhibitors, Retrospective Studies, Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, bladder cancer, urinary tract neoplasms, urothelial carcinoma, immunotherapy, outcomes, #uroonc, #utuc, #BladderCancer, #blcsm, Urology & Nephrology

جغرافية الموضوع: 592 - 603

وصف الملف: application/pdf

العلاقة: qt8678m8j9; https://escholarship.org/uc/item/8678m8j9Test

الإتاحة: https://escholarship.org/uc/item/8678m8j9Test

المؤلفون: Talukder, Rafee, Makrakis, Dimitrios, Diamantopoulos, Leonidas N, Carril-Ajuria, Lucia, Castellano, Daniel, De Kouchkovsky, Ivan, Koshkin, Vadim S, Park, Joseph J, Alva, Ajjai, Bilen, Mehmet A, Stewart, Tyler F, McKay, Rana R, Santos, Victor S, Agarwal, Neeraj, Jain, Jayanshu, Zakharia, Yousef, Morales-Barrera, Rafael, Devitt, Michael E, Grant, Michael, Lythgoe, Mark P, Pinato, David J, Nelson, Ariel, Hoimes, Christopher J, Shreck, Evan, Gartrell, Benjamin A, Sankin, Alex, Tripathi, Abhishek, Zakopoulou, Roubini, Bamias, Aristotelis, Murgic, Jure, Fröbe, Ana, Rodriguez-Vida, Alejo, Drakaki, Alexandra, Liu, Sandy, Kumar, Vivek, Lorenzo, Giuseppe Di, Joshi, Monika, Velho, Pedro Isaacsson, Buznego, Lucia Alonso, Duran, Ignacio, Moses, Marcus, Barata, Pedro, Sonpavde, Guru, Yu, Evan Y, Wright, Jonathan L, Grivas, Petros, Khaki, Ali Raza

المصدر: Clinical Genitourinary Cancer, vol 20, iss 2

مصطلحات موضوعية: Cancer, Clinical Research, HIV/AIDS, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Good Health and Well Being, Adjuvants, Immunologic, Administration, Intravesical, BCG Vaccine, Carcinoma, Transitional Cell, Humans, Immune Checkpoint Inhibitors, Neoplasm Recurrence, Local, Retrospective Studies, Urinary Bladder Neoplasms, Bladder cancer, BCG, Immunotherapy, Outcomes, Urinary tract neoplasms, Oncology and Carcinogenesis, Public Health and Health Services, Oncology & Carcinogenesis

جغرافية الموضوع: 165 - 175

وصف الملف: application/pdf

العلاقة: qt9mh6t47q; https://escholarship.org/uc/item/9mh6t47qTest

الإتاحة: https://escholarship.org/uc/item/9mh6t47qTest

المؤلفون: Khaki, Ali Raza, Li, Ang, Diamantopoulos, Leonidas N, Miller, Natalie J, Carril-Ajuria, Lucia, Castellano, Daniel, De Kouchkovsky, Ivan, Koshkin, Vadim, Park, Joseph, Alva, Ajjai, Bilen, Mehmet A, Stewart, Tyler, Santos, Victor, Agarwal, Neeraj, Jain, Jayanshu, Zakharia, Yousef, Morales-Barrera, Rafael, Devitt, Michael, Nelson, Ariel, Hoimes, Christopher J, Shreck, Evan, Gartrell, Benjamin A, Sankin, Alex, Tripathi, Abhishek, Zakopoulou, Roubini, Bamias, Aristotelis, Rodriguez-Vida, Alejo, Drakaki, Alexandra, Liu, Sandy, Kumar, Vivek, Lythgoe, Mark P, Pinato, David J, Murgic, Jure, Fröbe, Ana, Joshi, Monika, Isaacsson Velho, Pedro, Hahn, Noah, Alonso Buznego, Lucia, Duran, Ignacio, Moses, Marcus, Barata, Pedro, Galsky, Matthew D, Sonpavde, Guru, Yu, Evan Y, Shankaran, Veena, Lyman, Gary H, Grivas, Petros

المصدر: European Urology Oncology, vol 4, iss 3

مصطلحات موضوعية: Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Clinical Research, Patient Safety, Cancer, Digestive Diseases, Prevention, Liver Disease, Aged, Carcinoma, Transitional Cell, Cohort Studies, Female, Humans, Immune Checkpoint Inhibitors, Prognosis, Retrospective Studies, Urinary Bladder Neoplasms, Bladder cancer, Immunotherapy, Outcome research, Prognostic model, Urothelial carcinoma, Clinical sciences

جغرافية الموضوع: 464 - 472

وصف الملف: application/pdf

العلاقة: qt6ft7s89c; https://escholarship.org/uc/item/6ft7s89cTest

الإتاحة: https://escholarship.org/uc/item/6ft7s89cTest

المؤلفون: Makrakis, Dimitrios, Talukder, Rafee, Diamantopoulos, Leonidas N., Carril-Ajuria, Lucia, Castellano, Daniel, De Kouchkovsky, Ivan, Koshkin, Vadim S., Park, Joseph J., Alva, Ajjai, Bilen, Mehmet A., Stewart, Tyler F., McKay, Rana R., Santos, Victor S., Agarwal, Neeraj, Jain, Jayanshu, Zakharia, Yousef, Morales-Barrera, Rafael, Devitt, Michael E., Grant, Michael, Lythgoe, Mark P., Pinato, David J., Nelson, Ariel, Hoimes, Christopher J., Shreck, Evan, Gartrell, Benjamin A., Sankin, Alex, Tripathi, Abhishek, Zakopoulou, Roubini, Bamias, Aristotelis, Murgic, Jure, Fröbe, Ana, Rodriguez-Vida, Alejo, Drakaki, Alexandra, Liu, Sandy, Kumar, Vivek, Di Lorenzo, Giuseppe, Joshi, Monika, Isaacsson-Velho, Pedro, Buznego, Lucia Alonso, Duran, Ignacio, Moses, Marcus, Barata, Pedro, Sonpavde, Guru, Yu, Evan Y., Wright, Jonathan L., Grivas, Petros, Khaki, Ali Raza

مصطلحات موضوعية: #BladderCancer, bladder cancer, urinary tract neoplasms, urothelial carcinoma, immune checkpoint inhibitors, immunotherapy, outcomes, #uroonc, #utuc, #blcsm, Internal Medicine and Specialties, Health Sciences

وصف الملف: application/pdf

العلاقة: Makrakis, Dimitrios; Talukder, Rafee; Diamantopoulos, Leonidas N.; Carril-Ajuria, Lucia; Castellano, Daniel; De Kouchkovsky, Ivan; Koshkin, Vadim S.; Park, Joseph J.; Alva, Ajjai; Bilen, Mehmet A.; Stewart, Tyler F.; McKay, Rana R.; Santos, Victor S.; Agarwal, Neeraj; Jain, Jayanshu; Zakharia, Yousef; Morales-Barrera, Rafael; Devitt, Michael E.; Grant, Michael; Lythgoe, Mark P.; Pinato, David J.; Nelson, Ariel; Hoimes, Christopher J.; Shreck, Evan; Gartrell, Benjamin A.; Sankin, Alex; Tripathi, Abhishek; Zakopoulou, Roubini; Bamias, Aristotelis; Murgic, Jure; Fröbe, Ana; Rodriguez-Vida, Alejo; Drakaki, Alexandra; Liu, Sandy; Kumar, Vivek; Di Lorenzo, Giuseppe; Joshi, Monika; Isaacsson-Velho, Pedro; Buznego, Lucia Alonso; Duran, Ignacio; Moses, Marcus; Barata, Pedro; Sonpavde, Guru; Yu, Evan Y.; Wright, Jonathan L.; Grivas, Petros; Khaki, Ali Raza (2022). "Association of prior local therapy and outcomes with programmed- death ligand- 1 inhibitors in advanced urothelial cancer." BJU International (5): 592-603.; https://hdl.handle.net/2027.42/175056Test; BJU International; Bajorin DF, Witjes JA, Gschwend J, Schenker M. First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC). J Clin Oncol 2021; 39 ( 6_suppl ): 391; Abufaraj M, Gust K, Moschini M et al. Management of muscle invasive, locally advanced and metastatic urothelial carcinoma of the bladder: a literature review with emphasis on the role of surgery. Transl Androl Urol 2016; 5: 735 – 44; Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68: 7 – 30; Hussain MHA, Powles T, Albers P et al. IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC). J Clin Oncol 2020; 38 ( 15_suppl ): 5000; van Dijk N, Gil-Jimenez A, Silina K et al. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nat Med 2020; 26: 1839 – 44; Powles T, Kockx M, Rodriguez-Vida A et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat Med 2019; 25: 1706 – 14; Necchi A, Anichini A, Raggi D et al. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. J Clin Oncol 2018; 36: 3353 – 60; Horowitz M, Neeman E, Sharon E, Ben-Eliyahu S. Exploiting the critical perioperative period to improve long-term cancer outcomes. Nat Rev Clin Oncol 2015; 12: 213 – 26; Grivas P, Plimack ER, Balar AV et al. Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer (KEYNOTE-052): Outcomes in older patients by age and performance status. Eur Urol Oncol 2020; 3: 351 – 9; Sundahl N, Vandekerkhove G, Decaestecker K et al. Randomized phase 1 trial of pembrolizumab with sequential versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma. Eur Urol 2019; 75: 707 – 11; Daro-Faye M, Kassouf W, Souhami L et al. Combined radiotherapy and immunotherapy in urothelial bladder cancer: harnessing the full potential of the anti-tumor immune response. World J Urol 2021; 39: 1331 – 43; Rompré-Brodeur A, Shinde-Jadhav S, Ayoub M et al. PD-1/PD-L1 Immune checkpoint inhibition with radiation in bladder cancer. In Situ and Abscopal Effects. Mol Cancer Ther 2020; 19: 211 – 20; Moschini M, Xylinas E, Zamboni S et al. Efficacy of surgery in the primary tumor site for metastatic urothelial cancer: analysis of an international, multicenter. Multidisciplinary Database. Eur Urol Oncol 2020; 3: 94 – 101; Abufaraj M, Dalbagni G, Daneshmand S et al. The role of surgery in metastatic bladder cancer: a systematic review. Eur Urol 2018; 73: 543 – 57; Li R, Metcalfe M, Kukreja J, Navai N. Role of radical cystectomy in non-organ confined bladder cancer: a systematic review. Bladder Cancer 2018; 4: 31 – 40; Amin S, Baine MJ, Meza JL, Lin C. Association of immunotherapy with survival among patients with brain metastases whose cancer was managed with definitive surgery of the primary tumor. JAMA Netw Open 2020; 3: e2015444; Bellmunt J, Choueiri TK, Fougeray R et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 2010; 28: 1850 – 5; Harris PA, Taylor R, Thielke R et al. Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42: 377 – 81; Harris PA, Taylor R, Minor BL et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform 2019; 95: 103208; Khaki AR, Li A, Diamantopoulos LN et al. Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. Cancer 2020; 126: 1208 – 16; Esagian SM, Khaki AR, Diamantopoulos LN et al. Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. BJU Int 2021; 128: 196 – 205; Khaki AR, Li A, Diamantopoulos LN et al. A new prognostic model in patients with advanced urothelial carcinoma treated with first-line immune checkpoint inhibitors [published online ahead of print, 2021 Jan 7]. Eur Urol Oncol 2021; 4: 464 – 72; Miller NJ, Khaki AR, Diamantopoulos LN et al. Histological subtypes and response to PD-1/PD-L1 blockade in advanced urothelial cancer: a retrospective study. J Urol 2020; 204: 63 – 70; Singla N, Hutchinson RC, Ghandour RA et al. Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database. Urol Oncol 2020; 38: 604.e9 – 604.e17; Gopalakrishnan D, Koshkin VS, Ornstein MC et al. Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook. Ther Clin Risk Manag 2018; 14: 1019 – 40; Powles T, Durán I, van der Heijden MS et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2018; 391: 748 – 57; Powles T, Park SH, Voog E et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 2020; 383: 1218 – 30; Sargos P, Baumann BC, Eapen L et al. Risk factors for loco-regional recurrence after radical cystectomy of muscle-invasive bladder cancer: A systematic-review and framework for adjuvant radiotherapy. Cancer Treat Rev 2018; 70: 88 – 97; Mari A, Campi R, Tellini R et al. Patterns and predictors of recurrence after open radical cystectomy for bladder cancer: a comprehensive review of the literature. World J Urol 2018; 36: 157 – 70; Moschini M, Zamboni S, Karnes JR et al. Clinical recurrence after radical cystectomy for bladder cancer, defining optimal surveillance after surgery. Eur Urol Supp 2019; 18: e1144

الإتاحة: https://doi.org/10.1111/bju.15603Test
https://hdl.handle.net/2027.42/175056Test

المؤلفون: Esagian, Stepan M., Khaki, Ali Raza, Diamantopoulos, Leonidas N., Carril‐ajuria, Lucia, Castellano, Daniel, De Kouchkovsky, Ivan, Park, Joseph J., Alva, Ajjai, Bilen, Mehmet A., Stewart, Tyler F., McKay, Rana R., Santos, Victor S., Agarwal, Neeraj, Jain, Jayanshu, Zakharia, Yousef, Morales‐barrera, Rafael, Devitt, Michael E., Nelson, Ariel, Hoimes, Christopher J., Shreck, Evan, Gartrell, Benjamin A., Sankin, Alex, Tripathi, Abhishek, Zakopoulou, Roubini, Bamias, Aristotelis, Rodriguez‐vida, Alejo, Drakaki, Alexandra, Liu, Sandy, Kumar, Vivek, Lythgoe, Mark P., Pinato, David J., Murgic, Jure, Fröbe, Ana, Joshi, Monika, Isaacsson Velho, Pedro, Hahn, Noah, Alonso Buznego, Lucia, Duran, Ignacio, Moses, Marcus, Barata, Pedro, Galsky, Matthew D., Sonpavde, Guru, Yu, Evan Y., Msaouel, Pavlos, Koshkin, Vadim S., Grivas, Petros

مصطلحات موضوعية: upper tract urothelial cancer, variant histology, #utuc, #uroonc, bladder cancer, checkpoint inhibitor, immunotherapy, Internal Medicine and Specialties, Health Sciences

وصف الملف: application/pdf

العلاقة: Esagian, Stepan M.; Khaki, Ali Raza; Diamantopoulos, Leonidas N.; Carril‐ajuria, Lucia; Castellano, Daniel; De Kouchkovsky, Ivan; Park, Joseph J.; Alva, Ajjai; Bilen, Mehmet A.; Stewart, Tyler F.; McKay, Rana R.; Santos, Victor S.; Agarwal, Neeraj; Jain, Jayanshu; Zakharia, Yousef; Morales‐barrera, Rafael; Devitt, Michael E.; Nelson, Ariel; Hoimes, Christopher J.; Shreck, Evan; Gartrell, Benjamin A.; Sankin, Alex; Tripathi, Abhishek; Zakopoulou, Roubini; Bamias, Aristotelis; Rodriguez‐vida, Alejo; Drakaki, Alexandra; Liu, Sandy; Kumar, Vivek; Lythgoe, Mark P.; Pinato, David J.; Murgic, Jure; Fröbe, Ana; Joshi, Monika; Isaacsson Velho, Pedro; Hahn, Noah; Alonso Buznego, Lucia; Duran, Ignacio; Moses, Marcus; Barata, Pedro; Galsky, Matthew D.; Sonpavde, Guru; Yu, Evan Y.; Msaouel, Pavlos; Koshkin, Vadim S.; Grivas, Petros (2021). "Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes." BJU International (2): 196-205.; https://hdl.handle.net/2027.42/168446Test; BJU International; European Cancer Information System. Cancer burden statistics and trends across Europe %7C ECIS [Internet]. Available at: https://ecis.jrc.ec.europa.eu/index.phpTest. Accessed September 2020; National Cancer Institute. Bladder Cancer - Cancer Stat Facts [Internet]. Available at: https://seer.cancer.gov/statfacts/html/urinb.htmlTest. Accessed September 2020; Khaki AR, Li A, Diamantopoulos LN et al. Impact of performance status on treatment outcomes: a real- world study of advanced urothelial cancer treated with immune checkpoint inhibitors. Cancer 2020; 126: 1208 - 16; Palmer AC, Sorger PK. Combination cancer therapy can confer benefit via patient- to- patient variability without drug additivity or synergy. Cell 2017; 171: 1678 - 91.e13; Grivas P, Sternberg CN, Agarwal N et al. 796TiP TROPHY- U- 01 Cohort 3: sacituzumab govitecan (SG) and pembrolizumab (pembro) in patients (pts) with progression or recurrence of metastatic urothelial cancer (mUC) after platinum (PLT)- based therapy. Ann Oncol 2020; 1: S604 - S605; Grivas P, Drakaki A, Friedlander TW, Sonpavde G. Conceptual framework for therapeutic development beyond anti- PD- 1/PD- L1 in urothelial cancer. Am Soc Clin Oncol Educ B 2019; 39: 284 - 300; Khaki AR, Agarwal N, Pal SK, Grivas P. Immunotherapy- based combination strategies for advanced urothelial cancer: a long quest. Cancer 2020; 126: 4446 - 50; Barata PC, Koshkin VS, Funchain P et al. Next- generation sequencing (NGS) of cell- free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance. Ann Oncol 2017; 28: 2458 - 63; Grivas P, Lalani AK, Pond GR et al. Circulating tumor DNA alterations in advanced urothelial carcinoma and association with clinical outcomes: a pilot study. Eur Urol Oncol 2020; 3: 695 - 9; Christensen E, Birkenkamp- Demtröder K, Sethi H et al. Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra- deep sequencing of plasma cell- free DNA in patients with urothelial bladder carcinoma. J Clin Oncol 2019; 37: 1547 - 57; Pal SK, Bajorin D, Dizman N et al. Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell- free DNA results. Cancer 2020; 126: 2597 - 606; Nassar AH, Mouw KW, Jegede O et al. A model combining clinical and genomic factors to predict response to PD- 1/PD- L1 blockade in advanced urothelial carcinoma. Br J Cancer 2020; 122: 555 - 63; Sonpavde G, Manitz J, Gao C et al. Five- factor prognostic model for survival of post- platinum patients with metastatic urothelial carcinoma receiving PD- L1 inhibitors. J Urol 2020; 204: 1173 - 9; Powles T, Walker J, Andrew Williams J, Bellmunt J. The evolving role of PD- L1 testing in patients with metastatic urothelial carcinoma. Cancer Treat Rev 2020; 82: 101925; Le DT, Uram JN, Wang H et al. PD- 1 blockade in tumors with mismatch- repair deficiency. N Engl J Med 2015; 372: 2509 - 20; Catto JW, Azzouzi AR, Amira N et al. Distinct patterns of microsatellite instability are seen in tumours of the urinary tract. Oncogene 2003; 22: 8699 - 706; Santiago- Walker AE, Chen F, Loriot Y et al. Predictive value of fibroblast growth factor receptor (FGFR) mutations and gene fusions on anti- PD- (L)1 treatment outcomes in patients (pts) with advanced urothelial cancer (UC). J Clin Oncol 2019; 37 ( Suppl. ): 419; Wang L, Gong Y, Saci A et al. Fibroblast growth factor receptor 3 alterations and response to PD- 1/PD- L1 blockade in patients with metastatic urothelial cancer. Eur Urol 2019; 76: 599 - 603; Moss TJ, Qi Y, Xi L et al. Comprehensive genomic characterization of upper tract urothelial carcinoma. Eur Urol 2017; 72: 641 - 9; Audenet F, Isharwal S, Cha EK et al. Clonal relatedness and mutational differences between upper tract and bladder urothelial carcinoma. Clin Cancer Res 2019; 25: 967 - 76; Sweis RF, Spranger S, Bao R et al. Molecular drivers of the non- T- cell- inflamed tumor microenvironment in urothelial bladder cancer. Cancer Immunol Res 2016; 4: 563 - 8; Gajewski TF. Next hurdle in cancer immunorapy: overcoming non- T- cell- inflamed tumor microenvironment. Semin Oncol 2015; 42: 663 - 71.; Sharma P, Shen Y, Wen S et al. CD8 tumor- infiltrating lymphocytes are predictive of survival in muscle- invasive urothelial carcinoma. Proc Natl Acad Sci USA 2007; 104: 3967 - 72; Li H, Zhang Q, Shuman L et al. Evaluation of PD- L1 and other immune markers in bladder urothelial carcinoma stratified by histologic variants and molecular subtypes. Sci Rep 2020; 10: 1439; Robinson BD, Vlachostergios PJ, Bhinder B et al. Upper tract urothelial carcinoma has a luminal- papillary T- cell depleted contexture and activated FGFR3 signaling. Nat Commun 2019; 10: 2977; Miller NJ, Khaki AR, Diamantopoulos LN et al. Histological subtypes and response to PD- 1/PD- L1 blockade in advanced urothelial cancer: a retrospective study. J Urol 2020; 204: 63 - 70; McGregor BA, Campbell MT, Xie W et al. Phase II study of nivolumab and ipilimumab for advanced rare genitourinary cancers. J Clin Oncol 2020; 38 ( Suppl. ): 5018; Necchi A, Madison R, Pal SK et al. Comprehensive genomic profiling of upper- tract and bladder urothelial carcinoma. Eur Urol Focus 2020 [Online ahead of print]. https://doi.org/10.1016/j.euf.2020.08.001Test; Galsky MD, Banchereau R, Kadel EE et al. Biological features and clinical outcomes in atezolizumab (atezo)- treated patients (pts) with metastatic urothelial cancer (mUC) of the upper vs lower urinary tract (UTUC vs LTUC). Ann Oncol 2018; 29: viii321; Bellmunt J, Choueiri TK, Fougeray R et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum- containing regimens. J Clin Oncol 2010; 28: 1850 - 5; Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)- A metadata- driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42: 377 - 81; Sternberg CN, Loriot Y, James N et al. Primary results from SAUL, a multinational single- arm safety study of atezolizumab therapy for locally advanced or metastatic urothelial or nonurothelial carcinoma of the urinary tract. Eur Urol 2019; 76: 73 - 81; Patel MR, Ellerton J, Infante JR et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open- label, phase 1 trial. Lancet Oncol 2018; 19: 51 - 64; Sharma P, Retz M, Siefker- Radtke A et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single- arm, phase 2 trial. Lancet Oncol 2017; 18: 312 - 22; Balar AV, Castellano D, O- Donnell PH et al. First- line pembrolizumab in cisplatin- ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE- 052): a multicentre, single- arm, phase 2 study. Lancet Oncol 2017; 18: 1483 - 92; Galsky MD, Arija Jà , Bamias A et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo- controlled phase 3 trial. Lancet 2020; 395: 1547 - 57; Powles T, Durán I, van der Heijden MS et al. Atezolizumab versus chemotherapy in patients with platinum- treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open- label, phase 3 randomised controlled trial. Lancet 2018; 391: 748 - 57; Balar AV, Galsky MD, Rosenberg JE et al. Atezolizumab as first- line treatment in cisplatin- ineligible patients with locally advanced and metastatic urothelial carcinoma: a single- arm, multicentre, phase 2 trial. Lancet 2017; 389: 67 - 76; Rosenberg JE, Hoffman- Censits J, Powles T et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum- based chemotherapy: A single- arm, multicentre, phase 2 trial. Lancet 2016; 387: 1909 - 20; Powles T, Park SH, Voog E et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 2020; 383: 1218 - 30; Bellmunt J, de Wit R, Vaughn DJ et al. Pembrolizumab as second- line therapy for advanced urothelial carcinoma. N Engl J Med 2017; 376: 1015 - 26; Gopalakrishnan D, Koshkin VS, Ornstein MC, Papatsoris A, Grivas P. Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook. Ther Clin Risk Manag 2018; 14: 1019 - 40; Shao IH, Chang YH, Pang ST. Recent advances in upper tract urothelial carcinomas: from bench to clinics. Int J Urol 2019; 26: 148 - 59; Leow JJ, Chong KT, Chang SL, Bellmunt J Upper tract urothelial carcinoma: a different disease entity in terms of management. ESMO Open 2017; 1: e000126; Agarwal N, Pal SK, Hahn AW et al. Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. Cancer 2018; 124: 2115 - 24; Winters BR, De Sarkar N, Arora S et al. Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsy. JCI Insight 2019; 5: e128728; Green DA, Rink M, Xylinas E et al. Urothelial carcinoma of the bladder and the upper tract: Disparate twins. J Urol 2013; 189: 1214 - 21

الإتاحة: https://doi.org/10.1111/bju.15324Test
https://doi.org/10.1016/j.euf.2020.08.001Test
https://hdl.handle.net/2027.42/168446Test

المؤلفون: Morel, Alexandra Almanzar, Shreck, Evan, Mally, Pradeep V., Kim, Yang, Bailey, Sean M., Wachtel, Elena V.

المصدر: Journal of Perinatal Medicine ; volume 44, issue 6 ; ISSN 1619-3997 0300-5577

الإتاحة: https://doi.org/10.1515/jpm-2015-0210Test